Sophiris Bio to Present at the 13th Annual BIO Investor Forum

13th Annual BIO Investor Forum

SAN DIEGO & VANCOUVER, British Columbia--()--Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized prostate cancer, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 13th Annual BIO Investor Forum. The presentation is scheduled for Tuesday, October 7, 2014 at 8:00 a.m. PDT in San Francisco.

The presentation will be webcast live and can be accessed through the Company’s Investor Relations page at www.sophiris.com. A replay of the presentation will be available approximately one hour after the conclusion of the live presentation and available on the Company’s website for 90 days.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of the symptoms of BPH and treatment of localized prostate cancer. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of BPH and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris plans to initiate a Phase 2 proof of concept study of PRX302 for the treatment of localized prostate cancer in the second half of 2014. For more information, please visit www.sophiris.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, clinical trial enrollment and results, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Sophiris Bio Inc.
Peter Slover, 858-777-1760
Chief Financial Officer
or
Corporate Communications and Investor Relations:
Equicom Group
Michael Moore, 858-886-7813
Investor Relations
mmoore@tmxequicom.com
or
Canale Communications, Inc.
Jason I. Spark, 619-849-6005
Corporate Communications and IR
jason@canalecomm.com

Release Summary

Sophiris Bio Inc., a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate), will be presenting at BIO Investor Forum.

Contacts

Sophiris Bio Inc.
Peter Slover, 858-777-1760
Chief Financial Officer
or
Corporate Communications and Investor Relations:
Equicom Group
Michael Moore, 858-886-7813
Investor Relations
mmoore@tmxequicom.com
or
Canale Communications, Inc.
Jason I. Spark, 619-849-6005
Corporate Communications and IR
jason@canalecomm.com